Scientists track superbug infections to find better ways to fight them
NCT ID NCT07160569
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will follow 100 adults in southern Italy who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), a type of superbug. Researchers will analyze the bacteria's genes and resistance patterns, and track how patients respond to three specific antibiotics. The goal is to gather data that could help doctors choose the most effective treatments for these dangerous infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand which antibiotics work best for severe CRE infections, potentially guiding treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test a new drug or cure, and results may not apply to other regions or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARBAPENEM-RESISTANT ENTEROBACTERIACEAE INFECTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Policlinico Universtiario Agostino Gemelli IRCCS
Rome, Roma, 00168, Italy
-
Unit of Infectious and Tropical Diseases, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria
Reggio Calabria, Italy
-
Unit of Infectious and Tropical Diseases, Azienda Ospedaliera "Cannizzaro", Catania
Catania, Italy
-
Unit of Infectious and Tropical Diseases, University "Magna Graecia", Catanzaro
Catanzaro, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.